Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

China tightens Russian border checks, approves experimental coronavirus vaccine trials

Published 04/13/2020, 11:04 PM
Updated 04/14/2020, 01:47 AM
© Reuters. Resident wearing a face mask looks at a smartphone in the city centre in Suifenhe, a city of Heilongjiang province on the border with Russia, as the spread of coronavirus disease (COVID-19) continues in the country
SVA
-
MRNA
-
6185
-

By Yew Lun Tian and Huizhong Wu

SUIFENHE, China (Reuters) - China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus as it battles to contain imported cases, especially from neighbouring Russia, the new "front line" in the war on COVID-19.

Russia has become China's largest source of imported cases, with a total of 409 infections originating in the country, and Chinese citizens should stay put and not return home, the state-owned Global Times said in an editorial.

"Russia is the latest example of a failure to control imported cases and can serve as a warning to others," said the paper, which is run by the Communist Party's People's Daily.

"The Chinese people have watched Russia become a severely affected country... This should sound the alarm: China must strictly prevent the inflow of cases and avoid a second outbreak."

China's northeastern border province of Heilongjiang saw 79 new cases of imported coronavirus cases on Monday. All the new cases were Chinese citizens travelling back into the country from Russia, state media said on Tuesday. They formed the bulk of new cases on the Chinese mainland, which stood at 89.

Heilongjiang's provincial authority said on Tuesday that it had established a hotline to reward citizens for reporting illegal immigrants crossing into the province.

According to a notice, people supplying verified information about illegal cross-border crimes will be granted 3,000 yuan. Those who apprehend the illegal immigrants themselves and hand them over to the authorities will be given 5,000 yuan.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

As of Tuesday, China had reported 82,249 coronavirus cases and 3,341 deaths. There were no deaths in the past 24 hours.

Mongolia's health ministry also confirmed 13 new cases on Tuesday, all imported from Russia.

VACCINE TRIALS

As China fights to prevent a second wave of COVID-19, two experimental vaccines will be trialed on humans, state media Xinhua reported on Tuesday.

The experimental vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech (O:SVA), and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group.

In March, China gave the green-light for another clinical trial for a coronavirus vaccine candidate developed by military-backed China's Academy of Military Medical Sciences and HK-listed biotech firm CanSino Bio (HK:6185), shortly after U.S. drug developer Moderna (O:MRNA) said it had begun human tests for their vaccine with the U.S. National Institutes of Health.

At a meeting chaired by Premier Li Keqiang on Monday, China's coronavirus task force decided to deploy more health resources on its borders.

It said it would build hospitals and establish isolation points in border regions, and would also strengthen cooperation with neighbouring countries.

However, officials on Monday acknowledged that China's long border and its large number of country roads, paths, ferry crossings and mountain passes made it very difficult to control.

To ensure no infected people slip across the Russian-China border, China has put in stringent measures in Suifenhe a small city in Heilongjiang which shares a checkpoint with Russia.

Piao Minghua, deputy head of Harbin customs, which oversees Suifenhe border control, told Reuters that everyone entering Suifenhe has to be tested for the coronavirus, give detailed contact tracing, and then undergo quarantine.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Samples from inbound travellers are taken inside well-ventilated containers set up at the checkpoint so as to minimise cross-infection. Testing is being down round the clock to minimise waiting time.

Though the northeast border remains China's priority, state media also reported late on Monday that more than 100 people had been arrested in March for illegally entering China through its southwestern border in Yunnan province. Yunnan police have promised to step up controls over the border.

Thousands of people, mostly Chinese workers and traders, were flooding back into Yunnan from Laos and Myanmar earlier this month, putting huge pressures on border regions like Xishuangbanna.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.